ReviewFrontiers in cellular and infection microbiology2022
Abstract readReview
In one paragraph
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Plasmids of co-circulating Staphylococcus aureus serve as vehicles for antimicrobial resistance sharing across diseased host-species at short timescales.BMC microbiology · 2026Article
- Editorial for the Special Issue "Staphylococcal Biology and Pathogenesis".Antibiotics (Basel, Switzerland) · 2026Article
- Managing Bone Infections Beyond Systemic Antibiotics: A Scoping Review.Pathogens (Basel, Switzerland) · 2026Review
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Antimicrobial activity of brown propolis ethanolic extract and its application in intramammary formulation for the treatment of bovine mastitis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- From Antibiotic Resistance to Bacterial Vaccines: A New Approach to Controlling Resistant Bacterial Infections.Infection and drug resistance · 2026Review
- Emergence of a methicillin-susceptibleFrontiers in cellular and infection microbiology · 2026Article
- Comparative analysis of colonization and survival strategies of regionally predominant LA-MRSA clones ST398 and ST9.mSystems · 2025Article
- Overcoming Immune Evasion inACS infectious diseases · 2025Review
- STING contributes to the inflammation and proliferation ofInfection and immunity · 2025Article
- A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models.NPJ vaccines · 2025Article
- The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.Vaccine · 2025Article
- Implant-DerivedAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Article
- Staphylococcus aureus adapts to exploit collagen-derived proline during chronic infection.Nature microbiology · 2024Article
- Article
- Reduced Glycolysis and Cytotoxicity inInternational journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Tania Wong Fok LungDepartment of Pediatrics, Columbia University, New York, NY, United States.
Liana C ChanDepartment of Medicine, David Geffen School of Medicine at University of California Loss Angeles (UCLA), Los Angeles, CA, United States.
Alice PrinceDepartment of Pediatrics, Columbia University, New York, NY, United States.
Michael R YeamanDepartment of Medicine, David Geffen School of Medicine at University of California Loss Angeles (UCLA), Los Angeles, CA, United States.
Nathan K ArcherDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
M Javad AmanIntegrated BioTherapeutics, Rockville, MD, United States.
Richard A ProctorDepartment of Medicine and Medical Microbiology/Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MThe Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1MSystems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1MMultivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseR01AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI M Javad Aman · 2015 to 2026
$6.9MInnate Immune Clearance of Host-Adapted Pulmonary PathogensR35HL135800 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRINCE, ALICE S · 2017 to 2023
$5.9MProtective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infectionR01AI146177 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, ARCHER, NATHAN K. · 2020 to 2024
$3.5MIL-36 responses in Staphylococcus aureus driven skin inflammationR01AR073665 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ARCHER, NATHAN K. · 2018 to 2022
$1.8MMitigating Resistance & Virulence in MRSAR33AI111661 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2018
$1.2MMitigating Resistance & Virulence in MRSAR21AI111661 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2014 to 2015
$378kUnderstanding the immunometabolic response to Klebsiella pneumonia infectionK99HL157550 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WONG FOK LUNG, TANIA · 2022 to 2023
$244kNCATS NIH HHS KL2 TR001882NCATS NIH HHS UL1 TR001881NHLBI NIH HHS K99 HL157550NHLBI NIH HHS R35 HL135800NIAID NIH HHS R01 AI111205NIAID NIH HHS R01 AI146177NIAID NIH HHS R21 AI111661NIAID NIH HHS R33 AI111661NIAID NIH HHS U01 AI124319NIAMS NIH HHS R01 AR073665
Abstract
Despite meritorious attempts, a
Indexed as
Staphylococcal InfectionsVaccinesHumansImmune EvasionProspective StudiesStaphylococcus aureusVaccineshuman epigeneticshuman geneticsimmunityimmunometabolitesS. aureusvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.